This article is more than 5 years old. Information may no longer be current.

Clearside enrolls first patient in trial of triamcinolone acetonide formulation for DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first patient has been enrolled in the phase 1/2 HULK trial of Zuprata for the treatment of diabetic macular edema, according to a press release from Clearside Biomedical.

The open-label, multicenter study will enroll 20 patients with DME to assess the safety and efficacy of Zuprata (triamcinolone acetonide) administered to the suprachoroidal space with intravitreal Eylea (aflibercept, Regeneron), the release said. It will also test suprachoroidal Zuprata monotherapy.

Data regarding anatomical and functional outcomes and safety will be collected monthly during the 6-month evaluation period.